68Ga-NYM096 not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Using a syringe to withdraw 68Ga-NYM096 injection, the dose will be administered via an intravenous injection”In the company’s words, NCT07768306 on ClinicalTrials.gov
- Tested for
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Main trialPhase 1
- “68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC). The Phase 1 study is to evaluate the safety, pharmacokinetics, radioactivity distribution, radiation safety and preliminary diagnostic performance in participants with indeterminate renal masses (IRM)”In the company’s words, NCT07768306 on ClinicalTrials.gov
Other drugs for Clear Cell Renal Cell Carcinoma (ccRCC)
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- BelzutifanMerck & Co. · Phase 3
- AbexinostatXynomic Pharmaceuticals, Inc. · Phase 3
- DurvalumabAstraZeneca · Phase 3
- IpilimumabBristol Myers Squibb · Phase 3
- NivolumabBristol Myers Squibb · Phase 3
Coming up1
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Mar 2027 | Evaluation of Safety, Pharmacokinetics, Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026